Phiri, Kamija, Khairallah, Carole, Kwambai, Titus, Bojang, Kalifa, Dhabangi, Aggrey, Opoka, Robert, Idro, Richard, Stepniewska, Kasia, Boele van Hensbroek, Michael, John, Chandy C, Robberstad, Bjarne, Greenwood, Brian and terKuile, Feiko ORCID: https://orcid.org/0000-0003-3663-5617 (2024) 'Post-discharge Malaria Chemoprevention in Children Admitted with Severe Anaemia in Malaria-Endemic Settings in Africa: A systematic review and Individual Patient Data meta-analysis of randomised controlled trials'. Lancet Global Health, Vol 12, Issue 1, E33-E44.
Text
Order Confirmation.html - Additional Metadata Restricted to Repository staff only Download (14kB) |
||
|
Text
PIIS2214109X23004928.pdf - Published Version Available under License Creative Commons Attribution. Download (2MB) | Preview |
Abstract
Background: Severe anaemia is associated with high in-hospital mortality among young children. In malaria-endemic areas, surviving children also have an increased risk of mortality or readmission after hospital discharge. We conducted an individual patient data (IPD) meta-analysis to determine the efficacy of monthly post-discharge malaria chemoprevention (PDMC) in children recovering from severe anaemia.
Methods: Following PRISMA-IPD guidelines, we searched multiple databases, without time or language restrictions, for randomised controlled trials comparing monthly PDMC with placebo or standard-of-care among children admitted with severe anaemia in malaria-endemic Africa. Trials using daily or weekly malaria prophylaxis were not eligible. Fixed-effects two-stage meta-analysis of risk ratios (RR) was used to generate pooled effect estimates for mortality. Recurrent time-to-event data were analysed using one-stage mixed-effects Prentice-Williams-Peterson Total-Time models to obtain hazard ratios (HRs). This study is registered with PROSPERO-CRD42022308791.
Findings: Three double-blind placebo-controlled trials involving 3,663 children with severe anaemia fulfilled the eligibility criteria; 3,507 (95.7%) contributed to the modified intention-to-treat analysis. They received either monthly sulfadoxine-pyrimethamine until the end of the malaria transmission season (average 3.1 courses/child) (N=1,085, the Gambia), monthly artemether-lumefantrine given at the end of the 4th and 8th week post-discharge (N=1,373, Malawi), or monthly dihydroartemisinin-piperaquine given at the end of the 2nd, 6th, and 10th week post-discharge (N=1,049, Uganda and Kenya). During the period of chemoprevention, PDMC was associated with a 77% reduction in mortality (RR=0.23 [95% CI 0.08-0.70], p=0.0094, I2=0%) and a 55% reduction in all-cause readmissions (HR=0.45 [0.36-0.56], p<0.0001). The reductions were not sustained after protective drug levels had waned. The small number of trials limited our ability to assess heterogeneity, its sources and publication bias.
Interpretation: In malaria-endemic Africa, PDMC reduces mortality and readmissions in recently discharged children recovering from severe anaemia. PDMC can be a valuable strategy for the post-discharge management of this high-risk group. Future research should focus on methods of PDMC delivery, options to prolong the protection duration, other hospitalised special risk groups, and interventions targeting non-malarial causes of post-discharge morbidity.
Item Type: | Article |
---|---|
Subjects: | WC Communicable Diseases > WC 20 Research (General) WC Communicable Diseases > Tropical and Parasitic Diseases > WC 750 Malaria WS Pediatrics > WS 20 Research (General) WS Pediatrics > Diseases of Children and Adolescents > By System > WS 300 Hemic and lymphatic system |
Faculty: Department: | Clinical Sciences & International Health > Clinical Sciences Department |
Digital Object Identifer (DOI): | https://doi.org/10.1016/S2214-109X(23)00492-8 |
Depositing User: | Tracy Seddon |
Date Deposited: | 19 Dec 2023 15:15 |
Last Modified: | 19 Dec 2023 15:15 |
URI: | https://archive.lstmed.ac.uk/id/eprint/23462 |
Statistics
Actions (login required)
Edit Item |